Day: September 26, 2025

U.S. President Donald Trump has announced sweeping tariffs on branded and patented pharmaceutical imports, effective October 1, 2025, with exemptions only for companies building U.S. plants. The 100% levy comes alongside duties on kitchen cabinets, furniture, and heavy trucks, sending global markets into a spin. Indian pharmaceutical firms, supplying nearly half of U.S. generics and a significant portion of biosimilars, are directly affected. Analysts warn of higher drug prices for American patients, legal challenges under trade law, and a reshuffling of supply chains that could take years. The move coincides with a controversial $100,000 fee for H-1B visas, adding pressure on Indian IT professionals. The next 30–180 days will reveal corporate strategies, diplomatic negotiations, and possible WTO disputes.